iCAN Digital Precision Cancer Medicine Flagship is part the Finnish national R&D flagship program funded by the Academy of Finland. The founding hosts are University of Helsinki and HUS Helsinki University Hospital.  We are based on the Meilahti medical campus – one of the major hubs of health sciences in Europe, with the first Nordic OECI-accredited Comprehensive Cancer Center at HUS, and cutting-edge cancer research at the Faculty of Medicine and the Institute of Molecular Medicine Finland FIMM/HiLIFE.

At the core of iCAN is the Flagship project, a large pan-cancer public-private research partnership. iCAN also hosts other research projects aligned with the iCAN aims and carried out by iCAN partners for discoveries, innovations and improved treatments.

iCAN operates in close collaboration with a broad range of organizations, both nationally and internationally. Patients are represented at all levels and citizen engagement is encouraged through co-creational activities. Broad collaboration ensures that high-quality research spurs innovations and applications that benefit patients and the society at large.

How iCAN is governed

iCAN is governed by a Steering Board, with representation from all founding partners. Execution is at the responsibility of the Executive Officer, Scientific Director, Executive Committee, as well as research, data and office teams and working groups. An international Scientific and Impact Advisory Board and a Patient and Citizen Advisory Board share expertise and provide valuable guidance. Find out more about the iCAN team.